Thank you for explanation and quantification.
1 Like
Wanted to share that if you are in the US and have insurance, itās definitely worth going to GOOD RX to apply for the nextetol copay card.
The card said for as low as $10.
The pharmacy contact the physician to ask for pre authorization
Yesterday, I ELATEDLY picked up my rx and the cost was ZERO (it might have been zero because I hit my yearly out of pocket max, but Iām not sure because Iām still having to pay for some things. I came close to kissing the pharmacist 
YMMV
4 Likes
I ran out of Bempedoic Acid for 20 days. I continued to dose Pitavastatin and Ezetimibe during this time. I noticed the return of ānormalā feelings of occasional mild aniexty. After resuming my Bempedoic Acid I noticed these feelings no longer arise again. I am wondering if anyone else has experienced such effects. I am not aware of a mechanism that would cause this, however as itās inhibiting a reaction a few steps before statins, itās plausible that there could be broader impact to other functions.
3 Likes
Iāve had a great reduction in anxiety, but I attributed it to other things like NAC and lithium. If Bempedoiic Acid does it as well, thatās one more bonus.
2 Likes
I have been taking BA for almost two years and had not thought of this, although I did notice definite but subtle CNS impact of telmisartan. I had a brief conversation with one LLM. I edited the conclusion to eliminate some redundancy.
Yes, there is a plausible biochemical basis, but it is probably indirect rather than a direct CNS anxiolytic effect. . . .
The strongest mechanistic candidate is reduced peripheral inflammatory tone. In randomized trials, bempedoic acid lowers hsCRP by roughly the low-20% range, and that hsCRP effect is only weakly correlated with LDL-C lowering, which argues that something more than simple lipid reduction is occurring. In a biomarker analysis of CLEAR Harmony, hsCRP fell substantially, whereas IL-6 did not show a meaningful reduction, so the anti-inflammatory effect looks real but incomplete.
That matters because anxiety syndromes appear, at least in a subset of patients, to have an inflammatory component. Meta-analytic data in generalized anxiety disorder found higher CRP and signals for higher TNF-Ī± in some studies, though heterogeneity was substantial. A broader meta-analysis across anxiety-related disorders also found elevations in pro-inflammatory cytokines such as IL-1Ī², IL-6, and TNF-Ī±. Separately, randomized-trial meta-analysis of TNF-Ī± inhibitors in chronic inflammatory disease showed a small reduction in anxiety, which supports the general proposition that lowering peripheral inflammatory signaling can modestly improve affective symptoms in some phenotypes.
At the enzyme level, this is mechanistically coherent. ACLY is an immunometabolic node: in activated macrophages, ACLY expression/activity rises, and ACLY inhibition reduces inflammatory mediators such as nitric oxide, ROS, and prostaglandin E2. TLR signaling also uses ACLY-derived acetyl-CoA to promote histone acetylation and inflammatory gene induction. So an inference that fits the biology is: bempedoic acid ā less ACLY-driven peripheral inflammatory signaling ā less inflammatory traffic into brain-affect networks ā less āsomaticā anxiety/arousal in susceptible individuals.
A direct brain mechanism is much less convincing. . . . There is, however, a 2025 mouse paper showing that bempedoic acid improved inflammation-induced depressive behavior, lowered peripheral TNF-Ī±, reduced brain NF-ĪŗB signaling, and restored brain serotonin.
My judgment is that the personal reports of reduced anxiety are biochemically plausible, but the best current model is not ābempedoic acid acts like an anxiolytic in the brain.ā It is more likely phenotype-specific indirect benefit, especially in people whose anxiety has a meaningful inflammatory/sickness-behavior component. The signal to watch would be whether the same individuals also show a fall in hsCRP or other inflammatory markers after starting therapy.
A useful next step would be to sketch the most plausible causal chain from ACLY inhibition to reduced anxiety symptoms and then identify which biomarkers would best test it in an n-of-1 setting.
2 Likes